Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis
- PMID: 28827830
- PMCID: PMC5565113
- DOI: 10.1371/journal.pone.0183586
Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis
Abstract
Background: This is the first meta-analysis to compare the treatment effects and safety of administering donepezil alone versus a combination of memantine and donepezil to treat patients with moderate to severe Alzheimer Disease, particularly regarding cognitive functions, behavioral and psychological symptoms in dementia (BPSD), and global functions.
Methods: PubMed, Medline, Embase, PsycINFO, and Cochrane databases were used to search for English and non-English articles for inclusion in the meta-analysis to evaluate the effect size and incidence of adverse drug reactions of different treatments.
Results: Compared with patients who received donepezil alone, those who received donepezil in combination with memantine exhibited limited improvements in cognitive functions (g = 0.378, p < .001), BPSD (g = -0.878, p < .001) and global functions (g = -0.585, p = .004). Gradual titration of memantine plus a fixed dose and gradual titration of donepezil as well as a fixed dose and gradual titration of memantine resulted in limited improvements in cognitive functions(g = 0.371, p = .005), BPSD(g = -0.913, p = .001), and global functions(g = -0.371, p = .001).
Conclusion: Both in the 24th week and at the final evaluation point, the combination of donepezil and memantine led to greater improvement in cognitive functions, BPSD, and global functions than did donepezil alone in patients with moderate to severe Alzheimer Disease.
Conflict of interest statement
Figures
Similar articles
-
Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.JAMA. 2004 Jan 21;291(3):317-24. doi: 10.1001/jama.291.3.317. JAMA. 2004. PMID: 14734594 Clinical Trial.
-
[Use of acetylcholinesterase inhibitors and memantine in Alzheimer-type dementia].Rev Esp Salud Publica. 2005 Nov-Dec;79(6):665-72. doi: 10.1590/s1135-57272005000600006. Rev Esp Salud Publica. 2005. PMID: 16457058 Spanish.
-
A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease.Drug Des Devel Ther. 2016 Oct 3;10:3267-3279. doi: 10.2147/DDDT.S86463. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27757016 Free PMC article. Review.
-
The effects of combine treatment of memantine and donepezil on Alzheimer's disease patients and its relationship with cerebral blood flow in the prefrontal area.Int J Geriatr Psychiatry. 2014 Sep;29(9):881-9. doi: 10.1002/gps.4074. Epub 2014 Jan 17. Int J Geriatr Psychiatry. 2014. PMID: 24436135 Clinical Trial.
-
Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.Drugs. 2012 Apr 16;72(6):789-802. doi: 10.2165/11631830-000000000-00000. Drugs. 2012. PMID: 22480339 Review.
Cited by
-
Novel Dual Acetyl- and Butyrylcholinesterase Inhibitors Based on the Pyridyl-Pyridazine Moiety for the Potential Treatment of Alzheimer's Disease.Pharmaceuticals (Basel). 2024 Oct 21;17(10):1407. doi: 10.3390/ph17101407. Pharmaceuticals (Basel). 2024. PMID: 39459045 Free PMC article.
-
Fabrication of Hybrid Coated Microneedles with Donepezil Utilizing Digital Light Processing and Semisolid Extrusion Printing for the Management of Alzheimer's Disease.Mol Pharm. 2024 Sep 2;21(9):4450-4464. doi: 10.1021/acs.molpharmaceut.4c00377. Epub 2024 Aug 20. Mol Pharm. 2024. PMID: 39163171 Free PMC article.
-
Alzheimer's disease and its treatment-yesterday, today, and tomorrow.Front Pharmacol. 2024 May 24;15:1399121. doi: 10.3389/fphar.2024.1399121. eCollection 2024. Front Pharmacol. 2024. PMID: 38868666 Free PMC article. Review.
-
Combination of Tramiprosate, Curcumin, and SP600125 Reduces the Neuropathological Phenotype in Familial Alzheimer Disease PSEN1 I416T Cholinergic-like Neurons.Int J Mol Sci. 2024 Apr 30;25(9):4925. doi: 10.3390/ijms25094925. Int J Mol Sci. 2024. PMID: 38732141 Free PMC article.
-
Public acceptability of lumbar puncture in the diagnosis of Alzheimer's disease: a questionnaire-based single center study in China.Am J Transl Res. 2023 Jun 15;15(6):4179-4187. eCollection 2023. Am J Transl Res. 2023. PMID: 37434808 Free PMC article.
References
-
- Kumar A, Singh A, Ekavali. A review on Alzheimer's disease pathophysiology and its management: An update. Pharmacol Rep. 2015;67(2):195–203. doi: 10.1016/j.pharep.2014.09.004 - DOI - PubMed
-
- Ehret MJ, Chamberlin KW. Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials? Clin Ther. 2015;37(8):1604–16. Epub 2015/07/01. doi: 10.1016/j.clinthera.2015.05.510 . - DOI - PubMed
-
- Deardorff WJ, Feen E, Grossberg GT. The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease. Drugs Aging. 2015;32(7):537–47. Epub 2015/06/03. doi: 10.1007/s40266-015-0273-x. . - DOI - PubMed
-
- Campos C, Rocha NBF, Vieira RT, Rocha SA, Telles-Correia D, Paes F, et al. Treatment of cognitive deficits in Alzheimer's disease: A psychopharmacological review. Psychiatria Danubina. 2016;28(1):2–12. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
